Sign In | Join Free | My howtoaddlikebutton.com
howtoaddlikebutton.com
Products
Search by Category
Wholesale Marketplace
Home > Cardiovascular Agents >

C10H12O3 CAS 2210 74 4 Ranolazine Drug 1 - 2-Methoxyphenoxy methyl oxirane

Categories Ranolazine Drug
Certification: GMP condition
Place of Origin: China
MOQ: 10KGS
Packaging Details: Drum
Usage: Ranolazine Hydrochloride Intermediate
CAS: 2210-74-4
Name: 1 - ( 2 - Methoxyphenoxy ) methyl oxidant
  • Haven't found right suppliers
  • Our buyer assistants can help you find the most suitable, 100% reliable suppliers from China.
  • And this service is free of charge.
  • we have buyer assistants who speak English, French, Spanish......and we are ready to help you anytime!
  • Submit Buying Request
    • Product Details
    • Company Profile

    C10H12O3 CAS 2210 74 4 Ranolazine Drug 1 - 2-Methoxyphenoxy methyl oxirane

    CAS : 2210-74-4 Ranolazine Intermediate 1 - ( 2 - Methoxyphenoxy ) methyl oxirane


    Chemical Name : 1 - ( 2 - Methoxyphenoxy ) methyl oxirane


    CAS No . : 2210-74-4


    Synonyms : Glycidyl 2 - Methoxyphenyl ethe r; 1 - ( Glycidyloxy ) - 2- methoxybenzene


    Molecular Formula : C10H12O3


    Molecular Weight : 180.2


    Appearance : Off white solid


    Melting Point : 33 - 36 Deg C


    Usage : Ranolazine Intermediate


    Description :


    Ranolazine is the active pharmaceuical Ingredient ( API ) of Ranexa which is used to treat chronic chest pain. It may be used concomitantly with other drugs such as ACE inhibitors , andangiotensin receptor blockers , antiplatelet therapy , β blockers , calcium channel blockers , lipid-lowering therapy and nitrates.


    It was first arrpoved by FDA in 2006 and marketed by Gilead. It was also approved by Europe EMEA in 2008.


    Syntex Inc. originally began the ranolazine development in 1985 and completed 61 studies till1994. Afterwards, Phase II studies were done but it was found that the formulation did not result in adequate plasma concentrations of drug. Then the sustained-release ( SR ) formulation was created.


    In 1996, CV Therapeutics got the North American and European rights to ranolazine from Syntex accquired by Roche in 1994 and then in 2006, accquired the remaining worldwide rights to ranolazine. In 2008 Menarini accquired exclusively rights for ranolazine in Europe and some other countries from CV and then Gilead accuired CV in 2009. Gilead expanded the partnership with Menarini to include additional countries in 2013.


    1 - ( 2 - Methoxyphenoxy ) methyl oxirane CAS No. : 2210-74-4 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our commercial products are manufactured without infringing such patents. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.


    Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.

    Product Tags:

    95635 55 5

      

    5294 61 1

      
    Quality C10H12O3 CAS 2210 74 4 Ranolazine Drug 1 - 2-Methoxyphenoxy methyl oxirane for sale
    Send your message to this supplier
     
    From:
    To: Asambly Chemicals Co. Ltd.
    Subject:
    Message:
    Characters Remaining: (0/3000)
     
    Inquiry Cart 0

    Home| Products| Suppliers| Quality Suppliers| Site Map |About Us |Contact Us |Help |关于我们 |联系我们

    Copyright © 2009 - 2019 howtoaddlikebutton.com. All rights reserved.